In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reconfiguring DTC with Patient Behavior in Mind

Executive Summary

While DTC ads work when the end consumer is an able judge of product performance, as with medications for seasonal allergies, sexual dysfunction, or hair loss, they don't work nearly as well for asymptomatic illnesses. For these conditions, DTC may help increase patient acquisition and trial, but often fails to improve long-term use, thus under-performing both clinical expectations for patients and financial expectations for manufacturers. Optimal DTC programs should integrate patient acquisition strategies with direct-to-patient support strategies such as, disease-state web sites, refill reminder programs, and financial incentives able to drive ongoing product use.

You may also be interested in...



Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.

Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.

Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.

Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.

Activating Consumers

A new survey shows top drug executives still question their ability to exploit consumer promotion. They've got good reason: while consumer promotion clearly works in driving patients to doctors, increasing diagnosis rates and increasing patient requests for specific products, large numbers of their switch requests are denied. To give consumers sufficient power to influence their physician's prescribing behavior--Effective Voice-companies need a deeper understanding of physician attitudes towards requests in general, the specific therapeutic area and the product vis-à-vis competition.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel